Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 20 January 2012 | By Alexander Gaffney, RAC
The European Medicines Agency (EMA) today called on EU national regulatory authorities, including France, UK and Italy, to withdraw their respective Marketing Authorizations (MA) for oral meprobamate-containing medications. The medication has been associated with severe side effects including overdose, coma and death.
Meprobamate is a prescription sedative medicine used to treat anxiety, alcohol withdrawal, migraine attacks, disgestive disorders, muscle tensions, muscle cramps and insomnia. It is currently available in France, the Netherlands, Finaland, Hungary, Italy, Romania, UK, Iceland and Norway.
The French regulatory authority, Afssaps, alerted EMA in July of 2011 that they intended to suspend the MA for meprobamate because of the long list of side effects, including confusion, loss of consciousness, addiction, severe withdrawal symptoms, overdose, coma and death.
After reviewing the medication, EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that "the benefits of meprobamate do not outweigh its risks", and recommended that all national authorities remove meprobamate from the market gradually over the next 15 months. CHMP further recommended that doctors stop prescribing the medication due to the unfavorable risk-benefit assessment.
Severe withdrawal symptoms are associated with stopping oral meprobamte-containing medications too quickly, and the CHMP found the difference between an adequate treatment dose and an overdose to be minor.
EMA's notice said that the European Commission will issue a decision on their opinion "in due course."
Tags: Withdraw, Sedative, Meprobamate, Latest News, CHMP, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.